J Crétin

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Thomas Aparicio, Sandrine Lavau‐Denès, Jean–Marc Phelip et al. · Annals of Oncology · 2015 · 111 citations · Full text

Medicine, Oncology, Pharmacology +8

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study

Claire Falandry, Marc Debled, T. Bachelot et al. · Breast Cancer Research and Treatment · 2008 · 49 citations

Medicine, Oncology, Pharmacology +9

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas Aparicio, Michel Ducreux, Roger Faroux et al. · European Journal of Cancer · 2018 · 46 citations · Full text

Medicine, Nutrition, Oncology +9

Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).

Bernard Dubray, V. Beckendorf, S. Guérif et al. · Journal of Clinical Oncology · 2011 · 37 citations

Medicine, Oncology, Radiation Oncology +16